Crystal form of tenofovir prodrug, preparation method and application of crystal form

The invention relates to a novel crystal form of 9-[(R)-2-[[(S)-[[[1-(isopropoxycarbonyl)-1-methyl]ethyl]amino]phenoxyphosphinyl]methoxyl]propyl]adenine fumarate, a preparation method and application of the novel crystal form. Specifically, the invention relates to the novel crystal form of 9-[(R)-2-[[(S)-[[[1-(isopropoxycarbonyl)-1-methyl]ethyl]amino]phenoxyphosphinyl]methoxyl]propyl]adenine fumarate shown as the formula (I), wherein an XRPD spectrum of the novel crystal form is characterized by at least comprising diffraction peaks at 2[theta]+/-0.20 degree of 5.08, 12.44, 13.18, 22.37, 23.37, and 28.56. The crystal form has characteristics of good bioavailability, significant drug effect, good stability, high yield, and high purity. The crystal form assists in selecting and designing a medicine administration route and in determining technical parameters of a medicine, thereby improving the production quality of the medicine.